When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With that in mind, new models were proposed, considering the orderly increment of biomarkers and the disease as a continuum, or the variable time needed for the disease’s progression. In 2011, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) created separate diagnostic recommendations for each stage of the disease continuum—preclinical, mild cognitive impairment, and dementia. However, new scientific advances have led them to create a unifying research framework in 2018 that, although not intended for clinical use as of yet, is a step toward shifting the focus from the clinical symptoms to the biological alterations and toward changing the future diagnostic and treatment possibilities. This review aims to discuss the role of biomarkers in the onset of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nonetheless, pathological changes in the brain begin during the preclinical stage, decades before clinical symptoms.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 10×
“In early AD, the first detectable signs that can be observed in a structural MRI are atrophy in the middle temporal lobe (affecting specially the hippocampus), and a decrease in the thickness of the cerebral cortex in regions that are vulnerable to AD [73–81].”
BackgroundInfluentialImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,696
An Energy Budget for Signaling in the Grey Matter of the Brain
Attwell, D., & Laughlin, S. B. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200110000-00001 · Cited by 3,543 · cited 1×
“In addition, it correlates with decreased levels of synaptophysin found post-mortem that indicate a loss of synaptic activity [58,59].”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“This could be due to differences in the processing of Aβ, to the capacity of resistance to pathological damage derived from the toxicity of Aβ and to compensatory mechanisms [106].”
BackgroundThe clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 1×
“Moreover, FDG uptake is inversely related to the cognitive deficit, that is to say, less uptake correlates with greater cognitive damage throughout the entire clinical spectrum of the disease [62] with a sensitivity and a specificity greater than 80% [63,64].”
BackgroundReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“Cognitively normal APOE4 carriers also have glucose hypometabolism [65,66], which is worse in homozygotes than in heterozygotes [67], and can be detected as early as the third decade of life [68].”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · cited 1×
“Therefore, PiB-PET is only recommended when other clinical evidences of dementia are present [19,26], even though it is considered a valid marker to help in the diagnosis [51].”
BackgroundJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“Cognitively normal APOE4 carriers also have glucose hypometabolism [65,66], which is worse in homozygotes than in heterozygotes [67], and can be detected as early as the third decade of life [68].”
BackgroundRates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“measurement of amyloid plaque burden [38–44] and correlate well with post-mortem studies [44,45].”
BackgroundAge, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“Furthermore, the cerebral load of PiB is inversely related to the levels of CSF Aβ [24,27,46].”
BackgroundTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 1×
“Although p-tau should be a more specific indicator of AD than t-tau, both t-tau [20] and p-tau [20,21] behave in a very similar way in AD, increasing their concentrations in CSF.”
BackgroundAssociation of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1424 · Cited by 865
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
über eigenartige Krankheitsfälle des späteren Alters
Alzheimer, A. (1911) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02866241 · Cited by 710
Neuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Tierney, M. C., Fisher, R. H., Lewis, A. J., Zorzitto, M. L., Snow, W. G., Reid, D. W., & Nieuwstraten, P. (1988) · Neurology · doi:10.1212/wnl.38.3.359 · Cited by 613
Small, G. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520360056039 · Cited by 604
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
Davatzikos, C., Bhatt, P., Shaw, L. M., Batmanghelich, K. N., & Trojanowski, J. Q. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.023 · Cited by 578
Conversion of amyloid positive and negative MCI to AD over 3 years: An 11 C-PIB PET study
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Någren, K., Bullock, R., Walker, Z., Kennedy, A., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 527
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495
Identifying and validating biomarkers for Alzheimer's disease
Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · cited 1×
“We can classify AD biomarkers, according to the method of analysis, into biochemical CSF biomarkers or imaging-derived biomarkers [12,13].”
MethodBobinski, M., de Leon, M. J., Wegiel, J., DeSanti, S., Convit, A., Saint Louis, L. A., Rusinek, H., & Wisniewski✠, H. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00476-5 · Cited by 455
Fox, N. C., Crum, W. R., Scahill, R. I., Stevens, J. M., Janssen, J. C., & Rossor, M. N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05408-3 · Cited by 455
Metabolic Mapping of Functional Activity in the Hypothalamo-Neurohypophysial System of the Rat
Schwartz, W. J., Smith, C. B., Davidsen, L., Savaki, H., Sokoloff, L., Mata, M., Fink, D. J., & Gainer, H. (1979) · Science · doi:10.1126/science.462184 · Cited by 454
Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series
Lim, A., Tsuang, D., Kukull, W., Nochlin, D., Leverenz, J., McCormick, W., Bowen, J., Teri, L., Thompson, J., Peskind, E. R., et al. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb02571.x · Cited by 451
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500579102 · Cited by 401
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults
Dickerson, B. C., Stoub, T. R., Shah, R. C., Sperling, R. A., Killiany, R. J., Albert, M. S., Hyman, B. T., Blacker, D., & deToledo-Morrell, L. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166e96 · Cited by 383
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy: A Case Report
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.431 · Cited by 341
Csernansky, J. G., Wang, L., Swank, J., Miller, J. P., Gado, M., McKeel, D., Miller, M. I., & Morris, J. C. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.12.036 · Cited by 328
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · cited 2×
“Therefore, PiB-PET is only recommended when other clinical evidences of dementia are present [19,26], even though it is considered a valid marker to help in the diagnosis [51].”
BackgroundAssociations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
Ossenkoppele, R., Smith, R., Ohlsson, T., Strandberg, O., Mattsson, N., Insel, P. S., Palmqvist, S., & Hansson, O. (2019) · Neurology · doi:10.1212/wnl.0000000000006875 · Cited by 317
Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal
Apostolova, L. G., Mosconi, L., Thompson, P. M., Green, A. E., Hwang, K. S., Ramirez, A., Mistur, R., Tsui, W. H., & de Leon, M. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.008 · Cited by 314
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314 · cited 1×
“[111] carried out a longitudinal study with high-risk subjects carrying autosomal dominant mutations and showed that the sequence and temporal dynamics of the biomarkers match the theoretical model.”
BackgroundPIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302
Jack, C. R., Therneau, T. M., Weigand, S. D., Wiste, H. J., Knopman, D. S., Vemuri, P., Lowe, V. J., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1971 · Cited by 300
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
Jagust, W., Reed, B., Mungas, D., Ellis, W., & DeCarli, C. (2007) · Neurology · doi:10.1212/01.wnl.0000269790.05105.16 · Cited by 298
Rusinek, H., De Santi, S., Frid, D., Tsui, W.-H., Tarshish, C. Y., Convit, A., & de Leon, M. J. (2003) · Radiology · doi:10.1148/radiol.2293021299 · Cited by 281
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
den Heijer, T., Geerlings, M. I., Hoebeek, F. E., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.57 · Cited by 258
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults
Dickerson, B. C., & Wolk, D. A. (2012) · Neurology · doi:10.1212/wnl.0b013e31823efc6c · Cited by 240
Varma, A. R., Snowden, J. S., Lloyd, J. J., Talbot, P. R., Mann, D. M. A., & Neary, D. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.184 · Cited by 238
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Biomarkers of Alzheimer's disease
Craig-Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217
Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women
Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H., & Blennow, K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100529 · Cited by 214
β-Amyloid and the Pathogenesis of Alzheimer's Disease
Flier, J. S., Underhill, L. H., Yankner, B. A., & Mesulam, M.-M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112263252605 · Cited by 207
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198
Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions
Robb, M. A., McInnes, P., & Califf, R. M. (2016) · JAMA · doi:10.1001/jama.2016.2240 · Cited by 183
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180 · cited 1×
“Moreover, FDG uptake is inversely related to the cognitive deficit, that is to say, less uptake correlates with greater cognitive damage throughout the entire clinical spectrum of the disease [62] with a sensitivity and a specificity greater than 80% [63,64].”
BackgroundWalji, A. M., Hostetler, E. D., Selnick, H., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., Connolly, B., Gantert, L., Holahan, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00166 · Cited by 180
Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., Durham, R., Soares, H., Kimmel, L., Friedman, D., Bergeson, J., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.021 · Cited by 179
Villemagne, V. L., Ataka, S., Mizuno, T., Brooks, W. S., Wada, Y., Kondo, M., Jones, G., Watanabe, Y., Mulligan, R., Nakagawa, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.285 · Cited by 174
Biological markers of amyloid β-related mechanisms in Alzheimer's disease
Hampel, H., Shen, Y., Walsh, D. M., Aisen, P., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 160
Stefanovski, L., Triebkorn, P., Spiegler, A., Díaz-Cortés, M.-A., Solodkin, A., Jirsa, V., McIntosh, A. R., Ritter, P., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00054 · Cited by 159
The molecular and genetic basis of AD: The end of the beginning: The 2000 Wartenberg lecture
Rosenberg, R. N. (2000) · Neurology · doi:10.1212/wnl.54.11.2045 · Cited by 157
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
Schott, J. M., Bartlett, J. W., Fox, N. C., Barnes, J., & for the Alzheimer's Disease Neuroimaging Initiative Investigators (2010) · Annals of Neurology · doi:10.1002/ana.22315 · Cited by 151
Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
van Loenhoud, A. C., van der Flier, W. M., Wink, A. M., Dicks, E., Groot, C., Twisk, J., Barkhof, F., Scheltens, P., Ossenkoppele, R., & Initiative, F. T. A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007821 · Cited by 148
Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A. M., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 144
Accuracy of clinical criteria for AD in the Honolulu–Asia Aging Study, a population-based study
Petrovitch, H., White, L. R., Ross, G. W., Steinhorn, S. C., Li, C. Y., Masaki, K. H., Davis, D. G., Nelson, J., Hardman, J., Curb, J. D., et al. (2001) · Neurology · doi:10.1212/wnl.57.2.226 · Cited by 138
The critical need for defining preclinical biomarkers in Alzheimer's disease
Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.015 · Cited by 131
Ringman, J. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.642 · Cited by 124
Fortea, J., Sala‐Llonch, R., Bartrés‐Faz, D., Lladó, A., Solé‐Padullés, C., Bosch, B., Antonell, A., Olives, J., Sánchez‐Valle, R., Molinuevo, J. L., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.017 · Cited by 118
Silverberg, N. B., Elliott, C. L., Ryan, L. M., Masliah, E., & Hodes, R. J. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.004 · Cited by 115
Sojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletnikova, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113
Ewers, M., Brendel, M., Rizk-Jackson, A., Rominger, A., Bartenstein, P., Schuff, N., & Weiner, M. W. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.10.018 · Cited by 111
Driscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104
Petrie, E. C., Cross, D. J., Galasko, D., Schellenberg, G. D., Raskind, M. A., Peskind, E. R., & Minoshima, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.59 · Cited by 100
Familial Alzheimer disease: Decreases in CSF Aβ 42 levels precede cognitive decline
Moonis, M., Swearer, J. M., Dayaw, M. P. E., St. George-Hyslop, P., Rogaeva, E., Kawarai, T., & Pollen, D. A. (2005) · Neurology · doi:10.1212/01.wnl.0000171397.32851.bc · Cited by 95
Bendlin, B. B., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., Willette, A. A., Okonkwo, O. C., Sodhi, A., Ries, M. L., Birdsill, A. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037720 · Cited by 91 · cited 1×
“Interestingly, it has been shown that cognitively normal carriers of the Apolipoprotein ε4 allele (APOE4), who are at risk for late-onset AD, also show decreased levels of Aβ in CSF [33,34].”
BackgroundMartin, S. B., Smith, C. D., Collins, H. R., Schmitt, F. A., & Gold, B. T. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.010 · Cited by 80
Neural Network Modeling of Memory Deterioration in Alzheimer's Disease
Horn, D., Ruppin, E., Usher, M., & Herrmann, J. M. (1993) · Neural Computation · doi:10.1162/neco.1993.5.5.736 · Cited by 74
Kazee, A. M., Eskin, T. A., Lapham, L. W., Gabriel, K. R., McDaniel, K. D., & Hamill, R. W. (1993) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199307030-00004 · Cited by 70
Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 70
Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer’s Disease
Petrella, J. R., Hao, W., Rao, A., Doraiswamy, P. M., & Initiative, F. T. A. D. C. M. (2019) · Computational and Mathematical Methods in Medicine · doi:10.1155/2019/6216530 · Cited by 70
Koychev, I., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B., Sahakian, B. J., Rowe, J. B., Thomas, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170129 · Cited by 69
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, M., Almkvist, O., Axelman, K., Stefanova, E. D., Wall, A. E., Westman, E., Långström, B., Lannfelt, L., Graff, C., & Nordberg, A. K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.016 · Cited by 60
Ding, X., Bucholc, M., Wang, H., Glass, D. H., Wang, H., Clarke, D. H., Bjourson, A. J., Dowey, L. R. C., O’Kane, M., Prasad, G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27997-8 · Cited by 56
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55
Anastasio, T. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00016 · Cited by 49
Data-driven modeling of Alzheimer Disease pathogenesis
Anastasio, T. J. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.08.038 · Cited by 48
Roberts, P. D., Spiros, A., & Geerts, H. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt153 · Cited by 47
Investigating Interventions in Alzheimer's Disease with Computer Simulation Models
Proctor, C. J., Boche, D., Gray, D. A., & Nicoll, J. A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073631 · Cited by 44
Defrancesco, M., Egger, K., Marksteiner, J., Esterhammer, R., Hinterhuber, H., Deisenhammer, E. A., & Schocke, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106062 · Cited by 37
The Pathogenesis and Progression of the Pathological Changes of Alzheimer's Disease
Mann, D. M. A. (1989) · Annals of Medicine · doi:10.3109/07853898909149200 · Cited by 37
A Simulation Model of Periarterial Clearance of Amyloid-β from the Brain
Diem, A. K., Tan, M., Bressloff, N. W., Hawkes, C., Morris, A. W. J., Weller, R. O., & Carare, R. O. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00018 · Cited by 35
Geerts, H., Spiros, Ä., & Roberts, P. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0343-5 · Cited by 35
Lafirdeen, A. S. M., Cognat, E., Sabia, S., Hourrègue, C., Lilamand, M., Dugravot, A., Bouaziz-Amar, É., Laplanche, J., Hugon, J., Singh‐Manoux, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217026 · Cited by 24
Alzheimer's disease as a presumptive threshold phenomenon
Arendt, T., & Bigl, V. (1987) · Neurobiology of Aging · doi:10.1016/0197-4580(87)90131-x · Cited by 23
Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
on behalf of the Deep and Frequent Phenotyping study team, Firouzian, A., Whittington, A., Searle, G. E., Koychev, I. G., Zamboni, G., Lovestone, S., & Gunn, R. N. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0371-y · Cited by 22
Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer’s DiseasePreprint
Petrella, J. R., Hao, W., Rao, A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/313353 · Cited by 7
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“4,20,21 Therefore, it ’ s crucial to concentrate on the preclinical and MCI stages, where early intervention and management of modi fi able risk factors could potentially lower the risk of onset or delay the progression of disease.”
BackgroundThe complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 309
Pontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3392 · Cited by 261
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167
Cognitive Decline in Early and Premature Menopause
Sochocka, M., Karska, J., Pszczołowska, M., Ochnik, M., Fułek, M., Fułek, K., Kurpas, D., Chojdak-Łukasiewicz, J., Rosner‐Tenerowicz, A., & Leszek, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076566 · Cited by 164
Metadata
- Authors
- Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P.
- Affiliations
- Universitat de València (ES)
- Department of Clinic Neurophysiology. University Clinic Hospital of Valencia, Avda. Blasco Ibanez, 19, 46010 Valencia, Spain
- Department of Human Anatomy and Embriology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Corresponding author
- Lloret, Ana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-06
- Volume
- 20
- Issue
- 22
- Pages
- 5536
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6888399
- OpenAlex
- W2985526400
- Cited by
- 131
- References
- 117
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 19 · 2020: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2016-75508-R)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, disease onset, biomarkers, preclinical Alzheimer's disease, mild cognitive impairment, dementia, amyloid-beta, tau protein, glucose hypometabolism, brain atrophy, NIA-AA criteria, disease continuum, early diagnosis
- MeSH terms
- Alzheimer Disease, Humans, Risk Factors, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.